Login Register Cart 0
Generic placeholder image

Current Women`s Health Reviews

Editor-in-Chief

ISSN (Print): 1573-4048
ISSN (Online): 1875-6581

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by the Africa Middle East Cancer Inter-group [AMCI]

Author(s): Mudieddine Seoud, Amel Ladjeroud, Hassan Jaafar, Mohsen Mokhtar, Ozgur Ozyilkan, Shadi Alkhayyat, Shaheenah Dawood, Zafer Arik and Hamdy A. Azim*

Volume 20, Issue 1, 2024

Published on: 16 February, 2023

Article ID: e211022210275 Pages: 14

DOI: 10.2174/1573404819666221021091708

Price: $65

Abstract

Worldwide, ovarian cancer (OC) is one of the leading causes of cancer-related death among women. Despite the recent progress in the treatment of advanced OC, oncologists in many parts of the world still face several difficulties and constraints in the daily management of their patients. In addition to the shortage of resources and expertise, non-adherence to the up to date international guidelines has been identified as a major obstacle towards the improvement of treatment outcomes in the majority of developing countries, including the Middle East and North African (MENA) countries. A multidisciplinary gynecological oncology panel from the MENA region met virtually in December 2020 to discuss the challenges and hurdles faced by the community oncologists in the management of advanced OC. This manuscript reviews the key molecular and clinical studies that shaped the current international guidelines and suggests several modifications to make them more adaptable to the health status of developing countries of this region.

Graphical Abstract

[1]
Cancer today. 2021. Available from: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population= countries&population=900&populations=900&key=asr&sex= 2&cancer=39&type=0&statistic=5&prevalence=0&population_gr oup=0&ages_group%5B%5D=0&ages_group%5B%5D=17&grou p_cancer=1&include_nmsc=1&include_nmsc_other=1
[2]
Cancer Tomorrow. 2021. Available from: https://gco.iarc.fr/tomorrow/en/dataviz/isotype?cancers=25&single_unit= 10000& types= 1&sexes=2
[3]
Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018; 68(4): 284-96.
[http://dx.doi.org/10.3322/caac.21456] [PMID: 29809280]
[4]
Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 2019; 68(4): caac.21559.
[http://dx.doi.org/10.3322/caac.21559] [PMID: 31099893]
[5]
Kroeger PT Jr, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 2017; 29(1): 26-34.
[http://dx.doi.org/10.1097/GCO.0000000000000340] [PMID: 27898521]
[6]
Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 2015; 5(11): 1137-54.
[http://dx.doi.org/10.1158/2159-8290.CD-15-0714] [PMID: 26463832]
[7]
Azim HA, Kassem L, Azim H. Integrating PARP inhibitors into the management of breast cancer: where are we? Chin Clin Oncol 2020; 10(5): 50.
[PMID: 33440946]
[8]
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15(8): 852-61.
[http://dx.doi.org/10.1016/S1470-2045(14)70228-1] [PMID: 24882434]
[9]
Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003; 72(5): 1117-30.
[http://dx.doi.org/10.1086/375033] [PMID: 12677558]
[10]
Ovarian Cancer Risk Factors 2021. Available from: https://www.cancer.org/cancer/ovarian-cancer/causes-risks-prevention/risk-factors.html
[11]
Azribi F, Abdou E, Dawoud E, et al. 143P Prevalence of BRCA1/2 mutations in patients with ovarian cancer in the Gulf region: The PREDICT study. Ann Oncol 2020; 31: S296-7.
[http://dx.doi.org/10.1016/j.annonc.2020.08.264]
[12]
Alhuqail AJ, Alzahrani A, Almubarak H, et al. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients. Breast Cancer Res Treat 2018; 168(3): 695-702.
[http://dx.doi.org/10.1007/s10549-017-4635-4] [PMID: 29297111]
[13]
Bahsi T, Erdem HB. Spectrum of BRCA1/BRCA2 variants in 1419 Turkish breast and ovarian cancer patients: A single center study. Turk Biyokim Derg 2020; 45(1): 83-90.
[http://dx.doi.org/10.1515/tjb-2019-0424]
[14]
Farra C, Dagher C, Badra R, et al. BRCA mutation screening and patterns among high-risk Lebanese subjects. Hered Cancer Clin Pract 2019; 17(1): 4.
[http://dx.doi.org/10.1186/s13053-019-0105-9] [PMID: 30675319]
[15]
Ben Ayed-Guerfali D, Ben Kridis-Rejab W, Ammous-Boukhris N, et al. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia. J Transl Med 2021; 19(1): 108.
[http://dx.doi.org/10.1186/s12967-021-02772-y] [PMID: 33726785]
[16]
Laraqui A, Uhrhammer NEL, Rhaffouli H, Sekhsokh Y, Lahlou-Amine I, Bajjou T. BRCA genetic screening in middle eastern and north african: mutational spectrum and founder BRCA1 Mutation (c.798_799delTT) in North African. Dis Markers 2015; 2015194293
[17]
Siraj AK, Bu R, Iqbal K, et al. Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East. Hum Mutat 2019; 40(6): 729-33.
[http://dx.doi.org/10.1002/humu.23736] [PMID: 30825404]
[18]
Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol 2013; 3: 256.
[http://dx.doi.org/10.3389/fonc.2013.00256] [PMID: 24093089]
[19]
Referenced with permission from the NCCN Clinical practice guidelines in oncology (NCCN Guidelines®) for epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer V.1.2022.© national comprehensive cancer network, Inc. 2022. Available from: https://www.nccn.org
[20]
Zhang X, Meng X, Dou T, Sun H. Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses: A meta analysis. Exp Ther Med 2020; 20(6): 1.
[http://dx.doi.org/10.3892/etm.2020.9395] [PMID: 33199990]
[21]
American college of obstetricians and gynecologists’ committee on practice bulletins-gynecology. Practice bulletin no. 174: evaluation and management of adnexal masses. Obstet Gynecol 2016; 128(5): e210-26.
[http://dx.doi.org/10.1097/AOG.0000000000001768] [PMID: 27776072]
[22]
Timmerman D, Van Calster B, Testa A, et al. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol 2016; 214(4): 424-37.
[http://dx.doi.org/10.1016/j.ajog.2016.01.007] [PMID: 26800772]
[23]
Doubeni CA, Doubeni AR, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Physician 2016; 93(11): 937-44.
[PMID: 27281838]
[24]
Querleu D, Planchamp F, Chiva L, et al. European society of gynaecological oncology (ESGO) guidelines for ovarian cancer surgery. Int J Gynecol Cancer 2017; 27(7): 1534-42. [Available from: https://ijgc.bmj.com/content/27/7/1534
[http://dx.doi.org/10.1097/IGC.0000000000001041] [PMID: 30814245]
[25]
Burton E, Chase D, Yamamoto M, de Guzman J, Imagawa D, Berman ML. Surgical management of recurrent ovarian cancer: The advantage of collaborative surgical management and a multidisciplinary approach. Gynecol Oncol 2011; 120(1): 29-32.
[http://dx.doi.org/10.1016/j.ygyno.2010.10.008] [PMID: 21055797]
[26]
Vergote I, Coens C, Nankivell M, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol 2018; 19(12): 1680-7.
[http://dx.doi.org/10.1016/S1470-2045(18)30566-7] [PMID: 30413383]
[27]
Rutten MJ, van Meurs HS, van de Vrie R, et al. Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: A randomized controlled trial. J Clin Oncol 2017; 35(6): 613-21.
[http://dx.doi.org/10.1200/JCO.2016.69.2962] [PMID: 28029317]
[28]
Greggi S, Falcone F, Scaffa C, et al. Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey. Int J Gynecol Cancer 2020; 30(6): 819-24.
[http://dx.doi.org/10.1136/ijgc-2019-001172] [PMID: 32354792]
[29]
Fagotti A, Ferrandina G, Fanfani F, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 2006; 13(8): 1156-61.
[http://dx.doi.org/10.1245/ASO.2006.08.021] [PMID: 16791447]
[30]
Capone GL, Putignano AL, Trujillo Saavedra S, et al. Evaluation of a next-generation sequencing assay for BRCA1 and BRCA2 mutation detection. J Mol Diagn 2018; 20(1): 87-94.
[http://dx.doi.org/10.1016/j.jmoldx.2017.09.005] [PMID: 29061375]
[31]
Castéra L, Krieger S, Rousselin A, et al. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet 2014; 22(11): 1305-13.
[http://dx.doi.org/10.1038/ejhg.2014.16] [PMID: 24549055]
[32]
Sluiter MD, van Rensburg EJ. Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat 2011; 125(2): 325-49.
[http://dx.doi.org/10.1007/s10549-010-0817-z] [PMID: 20232141]
[33]
Ngoi NYL, Tan DSP. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? ESMO Open 2021; 6(3)100144
[http://dx.doi.org/10.1016/j.esmoop.2021.100144] [PMID: 34015643]
[34]
Telli ML, Timms KM, Reid J, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 2016; 22(15): 3764-73.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-2477] [PMID: 26957554]
[35]
Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol 2020; 38(11): 1222-45.
[http://dx.doi.org/10.1200/JCO.19.02960] [PMID: 31986064]
[36]
Randall LM, Pothuri B, Swisher EM, et al. Multi-disciplinary summit on genetics services for women with gynecologic cancers: a society of gynecologic oncology white paper. Gynecol Oncol 2017; 146(2): 217-24.
[http://dx.doi.org/10.1016/j.ygyno.2017.06.002] [PMID: 28596016]
[37]
Overview | Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer | Guidance | NICE. Available from: https://www.nice.org.uk/guidance/cg164
[38]
Owens DK, Davidson KW, Krist AH, et al. Risk assessment, genetic counseling, and genetic testing for BRCA -related cancer. JAMA 2019; 322(7): 652-65.
[http://dx.doi.org/10.1001/jama.2019.10987] [PMID: 31429903]
[39]
Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Libr 2011; 2016(9)CD007565
[http://dx.doi.org/10.1002/14651858.CD007565.pub2] [PMID: 21833960]
[40]
Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009; 114(1): 26-31.
[http://dx.doi.org/10.1016/j.ygyno.2009.03.018] [PMID: 19395008]
[41]
Chan JK, Kapp DS, Shin JY, et al. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol 2007; 109(6): 1342-50.
[http://dx.doi.org/10.1097/01.AOG.0000265207.27755.28] [PMID: 17540806]
[42]
Qin M, Jin Y, Ma L, Zhang YY, Pan LY. The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: A systematic review and meta-analysis of randomized controlled trials and observational studies. Oncotarget 2018; 9(9): 8614-28.
[http://dx.doi.org/10.18632/oncotarget.23808] [PMID: 29492221]
[43]
Fagotti A, Vizzielli G, Ferrandina G, et al. Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial). J Clin Oncol 2018; 36(15_suppl Suppl.): 5516-6.
[http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5516]
[44]
Onda T, Satoh T, Saito T, et al. Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602. J Clin Oncol 2018; 36(15_suppl Suppl.): 5500-0.
[http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5500]
[45]
Onda T, Satoh T, Saito T, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan clinical oncology group study JCOG0602. Eur J Cancer 2016; 64: 22-31.
[http://dx.doi.org/10.1016/j.ejca.2016.05.017] [PMID: 27323348]
[46]
Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363(10): 943-53.
[http://dx.doi.org/10.1056/NEJMoa0908806] [PMID: 20818904]
[47]
Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386(9990): 249-57.
[http://dx.doi.org/10.1016/S0140-6736(14)62223-6] [PMID: 26002111]
[48]
Fagotti A, Ferrandina G, Vizzielli G, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer 2016; 59: 22-33.
[http://dx.doi.org/10.1016/j.ejca.2016.01.017] [PMID: 26998845]
[49]
Coleridge SL, Bryant A, Kehoe S. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev 2021; (2): CD005343
[50]
van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018; 378(3): 230-40.
[http://dx.doi.org/10.1056/NEJMoa1708618] [PMID: 29342393]
[51]
Lim MC, Chang SJ, Yoo HJ, Nam BH, Bristow R, Park SY. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol 2017; 35(s15): 5520.
[http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5520]
[52]
Abdallah R, Seoud M, El Housheimi A, et al. Cytoreduction and hyperthermic intraperitoneal chemotherapy followed by hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) in advanced peritoneal carcinomatous (APC) at the american university of beirut medical center (AUBMC) experience 2007–2018: a retrospective review. Int J Gynecol Cancer 2019; 29: A394.
[http://dx.doi.org/10.1136/ijgc-2019-ESGO.743]
[53]
Al-Badawi IA, Abu-Zaid A, Azzam A, AlOmar O, AlHusaini H, Amin T. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management of recurrent/relapsed ovarian granulosa cell tumor: A single-center experience. J Obstet Gynaecol Res 2014; 40(9): 2066-75.
[http://dx.doi.org/10.1111/jog.12460] [PMID: 25181627]
[54]
Abu-Zaid A, Alomar O, Alsabban M, Salem H, Al-Badawi IA. A cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in primary advanced ovarian cancer: the first reported pilot experience from Saudi Arabia. Gulf J Oncolog 2020; 1(34): 19-25.
[PMID: 33431358]
[55]
Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003; 21(17): 3194-200.
[http://dx.doi.org/10.1200/JCO.2003.02.153] [PMID: 12860964]
[56]
Bookman MA. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs. combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J Clin Oncol 2006; 24(S18): 5002-2.
[http://dx.doi.org/10.1200/jco.2006.24.18_suppl.5002]
[57]
Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013; 14(10): 1020-6.
[http://dx.doi.org/10.1016/S1470-2045(13)70363-2] [PMID: 23948349]
[58]
Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2014; 15(4): 396-405.
[http://dx.doi.org/10.1016/S1470-2045(14)70049-X] [PMID: 24582486]
[59]
Chan JK, Brady MF, Penson RT, et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 2016; 374(8): 738-48.
[http://dx.doi.org/10.1056/NEJMoa1505067] [PMID: 26933849]
[60]
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365(26): 2473-83.
[http://dx.doi.org/10.1056/NEJMoa1104390]
[61]
Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365(26): 2484-96.
[http://dx.doi.org/10.1056/NEJMoa1103799] [PMID: 22204725]
[62]
Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial. Lancet Oncol 2015; 16(8): 928-36.
[http://dx.doi.org/10.1016/S1470-2045(15)00086-8] [PMID: 26115797]
[63]
Randall L, Burger R, Nguyen H, et al. Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab. Gynecol Oncol 2013; 130(1): e33-4.
[http://dx.doi.org/10.1016/j.ygyno.2013.04.139]
[64]
Liu S, Kasherman L, Fazelzad R, Wang L, Bouchard-Fortier G, Lheureux S. The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol 2021; 161(2): 601-12.
[http://dx.doi.org/10.1016/j.ygyno.2021.01.028]
[65]
Pfisterer J, Joly F, Kristensen G, et al. Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890). J Clin Oncol 2021; 39(S15): 5501-1.
[http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.5501]
[66]
Rouzier R, Gouy S, Selle F, et al. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. Eur J Cancer 2017; 70: 133-42.
[http://dx.doi.org/10.1016/j.ejca.2016.09.036] [PMID: 27914243]
[67]
Garcia Garcia Y, de Juan Ferré A, Mendiola C, et al. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer. Int J Gynecol Cancer 2019; 29(6): 1050-6.
[http://dx.doi.org/10.1136/ijgc-2019-000256] [PMID: 31263024]
[68]
Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354(1): 34-43.
[http://dx.doi.org/10.1056/NEJMoa052985] [PMID: 16394300]
[69]
Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2011; (11): CD005340
[http://dx.doi.org/10.1002/14651858.CD005340.pub3]
[70]
Walker JL, Brady MF, Wenzel L, et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG oncology/gynecologic oncology group study. J Clin Oncol 2019; 37(16): 1380-90.
[http://dx.doi.org/10.1200/JCO.18.01568] [PMID: 31002578]
[71]
Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18(9): 1274-84.
[http://dx.doi.org/10.1016/S1470-2045(17)30469-2] [PMID: 28754483]
[72]
Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016; 375(22): 2154-64.
[http://dx.doi.org/10.1056/NEJMoa1611310] [PMID: 27717299]
[73]
Matulonis U, Herrstedt J, Oza A, et al. Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer. Gynecol Oncol 2021; 162: S24-5.
[http://dx.doi.org/10.1016/S0090-8258(21)00693-4]
[74]
Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390(10106): 1949-61.
[http://dx.doi.org/10.1016/S0140-6736(17)32440-6] [PMID: 28916367]
[75]
Poveda A, Floquet A, Ledermann JA, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021; 22(5): 620-31.
[http://dx.doi.org/10.1016/S1470-2045(21)00073-5] [PMID: 33743851]
[76]
Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018; 379(26): 2495-505.
[http://dx.doi.org/10.1056/NEJMoa1810858] [PMID: 30345884]
[77]
Banerjee S, Moore KN, Colombo N, et al. 811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Ann Oncol 2020; 31: S613.
[http://dx.doi.org/10.1016/j.annonc.2020.08.950]
[78]
Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 2019; 381(25): 2403-15.
[http://dx.doi.org/10.1056/NEJMoa1909707] [PMID: 31562800]
[79]
González-Martín A, Pothuri B, Vergote I, Christensen RD, Graybill W, Mirza MR. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019; 381(25): 2391-402.
[http://dx.doi.org/10.1056/NEJMoa1910962]
[80]
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019; 381: 2416-8.
[http://dx.doi.org/10.1056/NEJMoa1911361]
[81]
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF. A randomized phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer. Lancet Oncol 2014; 15(11): 1207.
[http://dx.doi.org/10.1016/S1470-2045(14)70391-2] [PMID: 25218906]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy